ATRC News and Press, AtriCure Inc. From 11/03/21

AtriCure (NASDAQ:ATRC): Q3 GAAP EPS of $2.11. Revenue of $70.46M (+28.7% Y/Y) Press Release For further details see: AtriCure reports Q3 results

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. “Our results were driven by strong growth across key product lines, incl...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021. AtriCure will host a confer...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19 th Annual Global Healthcare Confere...

The following slide deck was published by AtriCure, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: AtriCure, Inc. 2021 Q2 - Results - Earnings Call Presentation

AtriCure, Inc. (ATRC) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Lynn Lewis – Investor Relations Mike Carrel – President and Chief Executive Officer Angie Wirick – Chief Financial Officer Conference Call Participants Rick Wise –...

Image source: The Motley Fool. AtriCure, inc (NASDAQ: ATRC) Q2 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure, inc (ATRC) Q2 2021 Earnings Call Transcript

AtriCure (NASDAQ:ATRC): Q2 GAAP EPS of -$0.36 misses by $0.02. Revenue of $71.4M (+74.9% Y/Y) beats by $10.32M. Press Release For further details see: AtriCure EPS misses by $0.02, beats on revenue

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by outperformance across our bu...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41 st Annual Growth Conference. AtriCur...